IGC Pharma Inc

General ticker "IGC" information:

  • Sector: Health Care
  • Industry: Pharmaceuticals
  • Capitalization: $28.2M

IGC Pharma Inc follows the US Stock Market performance with the rate: 9.0%.

Estimated limits based on current volatility of 4.1%: low 0.35$, high 0.38$

Factors to consider:

  • US accounted for 85.3% of revenue in the fiscal year ended 2023-03-31
  • Price in estimated range
  • Earnings for 3 months up through Q1 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-03-31 to 2026-03-31

  • 2024-03-31 to 2025-03-31 estimated range: [0.24$, 0.64$]
  • 2025-03-31 to 2026-03-31 estimated range: [0.26$, 0.68$]

Financial Metrics affecting the IGC estimates:

  • Negative: Non-GAAP EPS, $ of -0.22 <= 0.10
  • Negative: negative Net income
  • Negative: Operating profit margin, % of -87.93 <= 1.03
  • Negative: Operating cash flow per share per price, % of -20.29 <= 2.35
  • Positive: Interest expense per share, $ of 0 <= 0
  • Negative: Industry operating cash flow per share per price (median), % of -11.04 <= 3.85

Similar symbols

Short-term IGC quotes

Long-term IGC plot with estimates

Financial data

YTD 2022-03-31 2023-03-31 2024-03-31
Operating Revenue $0.40MM $0.91MM $1.34MM
Operating Expenses $15.82MM $12.48MM $11.14MM
Operating Income $-15.43MM $-11.57MM $-9.80MM
Non-Operating Income $0.41MM $0.07MM $-3.20MM
R&D Expense $2.33MM $3.46MM $3.77MM
Income(Loss) $-15.02MM $-11.51MM $-13.00MM
Profit(Loss) $-15.02MM $-11.51MM $-13.00MM
Stockholders Equity $23.89MM $14.91MM $7.32MM
Inventory $3.55MM $2.65MM $1.54MM
Assets $26.83MM $17.18MM $9.90MM
Operating Cash Flow $-7.46MM $-7.05MM $-5.20MM
Capital expenditure $0.74MM $0.62MM $0.52MM
Investing Cash Flow $-0.74MM $-0.23MM $-0.32MM
Financing Cash Flow $4.14MM $0.10MM $3.52MM
Earnings Per Share* $-0.29 $-0.22 $-0.22

* EPS are Split Adjusted, recent splits may be reflected with a delay.